Search | Clinical Trials Finder

Conditions: Endometrial Cancer
Interventions: Prolonged Overnight Fasting (POF), Blood Specimen Collection, Blood Sugar Monitor, Hysterectomy; Behavioral · Procedure · Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: PreDiabetes, Type 2 Diabetes, Healthy
Interventions: Time Restrictive Eating- late, Time Restrictive Eating- early, Time Restrictive Eating- early with early caloric intake, Macronutrient-controlled meals; Behavioral · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Stanford, California

Conditions: Cocaine Use Disorder
Interventions: Lorcaserin, Cocaine Intravenous (IV), Placebo comparator; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 59 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Coronary Artery Disease
Interventions: Sitagliptin, Placebo, Regular Human Insulin, Insulin glargine, Supplemental insulin (Insulin lispro), Supplemental insulin (Insulin aspart); Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 4
States / cities: Atlanta, Georgia

Conditions: Hyperglycemia
Interventions: Sitagliptin, Placebo, Supplemental insulin (insulin lispro), Supplemental insulin (insulin aspart), Long acting basal insulin (insulin detemir), Long acting basal insulin (insulin glargine); Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Diabetes, Hypoglycemia
Interventions: hyperinsulinemic-hypoglycemic clamp, 13C-MRS procedure/Acetate infusion; Other
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 40 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: PreDiabetes
Interventions: Intralipid and heparin, Saline; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 25 Years to 65 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Diabetes Mellitus, Type 2
Interventions: Intralipid 20%, Glucose infusion; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2009
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Lymphoproliferative Disorder
Interventions: rituximab, cyclophosphamide, methylprednisolone, prednisone; Biological · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 30 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2013
U.S. locations: 66
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 58 more

Conditions: Anal Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Cholangiocarcinoma, Colorectal Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Head and Neck Carcinoma, Hematopoietic and Lymphatic System Neoplasm, Hepatocellular Carcinoma, Lung Carcinoma, Malignant Adrenal Gland Neoplasm, Malignant Brain Neoplasm, Malignant Neoplasm of Unknown Primary, Malignant Solid Neoplasm, Malignant Testicular Neoplasm, Malignant Uterine Neoplasm, Neuroendocrine Neoplasm, Ovarian Carcinoma, Pancreatic Carcinoma, Penile Carcinoma, Pleural Carcinomatosis, Primary Peritoneal Carcinoma, Prostate Carcinoma, Salivary Gland Carcinoma, Sarcoma, Skin Carcinoma, Solitary Fibrous Tumor, Thymus Carcinoma, Thyroid Gland Carcinoma, Thyroid Gland Medullary Carcinoma, Urothelial Carcinoma, Vaginal Carcinoma
Interventions: Computed Tomography, Fludeoxyglucose F-18, Gallium Ga 68 FAPi-46, Positron Emission Tomography; Procedure · Other · Radiation
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Metabolic Syndrome
Interventions: intravenous glucose tolerance test, testosterone, anastrozole, goserelin acetate implant, aerobic capacity (VO2 Max), MRI, muscle biopsy, measurement of resting metabolic rate (energy expenditure), Dual energy x-ray absorptiometry, Fasting oral glucose tolerance test; Procedure · Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 50 Years to 75 Years · Male only
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 2
States / cities: Baltimore, Maryland • Boston, Massachusetts

Conditions: Human Gastrointestinal Physiology Data
Interventions: Glucotrol XL 5Mg Extended-Release Tablet, Glipizide ER 5 MG 24 HR Extended Release Oral Tablet, Rifaximin 200Mg Tab, 13C6-Glipizide; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Type 1 Diabetes Mellitus
Interventions: LY2605541, Insulin Lispro; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 17
States / cities: Concord, California • Escondido, California • Fresno, California + 14 more

Conditions: Type-2 Diabetes
Interventions: Full dose, Half dose, Control; Dietary Supplement
Lead sponsor: Loma Linda University; Other
Eligibility: 40 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Gestational Diabetes
Interventions: 2-hour 75-g oral glucose tolerance test and Dexcom G6 Pro continuous glucose monitor; Diagnostic Test
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Birmingham, Alabama • Chapel Hill, North Carolina

Conditions: Intracerebral Hemorrhage, Intracerebral Haemorrhage, Intraventricular Hemorrhage, Stroke, Cerebrovascular Disease
Interventions: Reversal of Oral anticoagulation within 30 minutes, Early intensive blood pressure lowering, Treatment of pyrexia, Hyperglycemia treatment, Do-not-resuscitate (DNR) or withdrawal of care, Referral to Intensive Care, Referral to Neurosurgery, Repeat brain imaging, Standard care; Other · Diagnostic Test
Lead sponsor: Region Skane; Other
Eligibility: 18 Years and older
Enrollment: 3,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Diabetes Mellitus
Interventions: BIOD-531, Humalog Mix 75/25, Humulin R U-500; Drug
Lead sponsor: Biodel; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2014
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Obesity, Heart Failure
Interventions: PET (Positron Emission Tomography), Echocardiogram, ^15O-water, 1-^11C-palmitate, 1-^11C-glucose; Procedure · Radiation
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 20 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2011
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Prediabetes, Insulin Resistance, Vascular Diseases
Interventions: Time-Restricted Feeding, Grazing; Other
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 35 Years to 70 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Gestational Diabetes
Interventions: Glyburide, Glucovance; Drug
Lead sponsor: Texas Tech University Health Sciences Center, El Paso; Other
Eligibility: 18 Years and older · Female only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: Obesity, Healthy
Interventions: PET Scan, Mixed Meal Test, Muscle sympathetic nerve activity (MSNA), Oral Glucose Tolerance Test, Body Composition, Percent Body Fat & Percent Body Water (Tanita scale), CT Scan, Body Composition, Percent Body Fat & Percent Body Water (DXA Scan); Diagnostic Test · Dietary Supplement · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Diabetes, NOS
Interventions: Dapagliflozin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Type 2 Diabetes
Interventions: Insulin glargine/lixisenatide (HOE901/AVE0010), Insulin glargine (HOE901), Metformin (Background Drug); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 736 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 108
States / cities: Birmingham, Alabama • Sun City, Arizona • Tempe, Arizona + 91 more

Conditions: Healthy
Interventions: PF-04308515, Prednisone; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Search by objective public record fields.

Fasting InTervention for Endometrial Cancer

Effect of Meal Composition and Timing Modification on Glucose Metabolism, Body Temperature and Sleep

Drug Interaction and Self Administration Studies of Compounds for Cocaine Use Disorder

Sitagliptin in Non-Diabetic Patients Undergoing Cardiac Surgery

Sitagliptin in Non-Diabetic Patients Undergoing General Surgery

Evaluating Glial Acetate Metabolism as a Biomarker of Hypoglycemic Counterregulation

Insulin and Insulin Pulses During Fasting

Mechanism Underlying Beta-cell Failure in Obese African Americans With History of Hyperglycemic Crises

Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

Insulin Sensitivity in Men With the Metabolic Syndrome

Pharmacokinetic Study of Single-Dose Modified Release Glipizide in Healthy Volunteers

A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus

Walnuts and Glucose Variability

Postpartum Glycemia in Women At Risk for Persistent Hyperglycemia

International Care Bundle Evaluation in Cerebral Hemorrhage Research

BIOD-531 vs. Humalog Mix 75/25 vs. Humulin R U-500 Post-Meal Glucose Control in Patients With Severe Insulin Resistance

Sex and Obesity: Effects on Heart Failure Study

Comparison of Time-Restricted Feeding Versus Grazing

Glyburide vs Glucovance in the Treatment of GDM

Sympathetic Activation in Obesity

Renal Mechanism of Action/Splay vs. TmG

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes

Single Dose Study Of PF-04308515 And Prednisone On Carbohydrate